Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
– 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy,... Read more.
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile – − Cardiovascular Magnetic... Read more.
United States Otorhinolaryngology KOLs Fair-Market Value Compensation Rates Report 2025: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “United States Fair-Market Value Compensation Rates for Otorhinolaryngology KOLs” report has been added to ResearchAndMarkets.com’s... Read more.
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable... Read more.
Real Reaches Settlement in Principle in Litigation With Former CFO
MIAMI–(BUSINESS WIRE)–The Real Brokerage Inc. (NASDAQ: REAX), a leading real estate technology platform redefining the industry through innovation and... Read more.
FIS Launches Innovative Asset Servicing Management Suite to Unlock Operational Efficiency Across Asset Servicing
Key facts FIS Asset Servicing Management Suite helps capital investment work harder by unlocking operational efficiencies across all areas of asset servicing. The... Read more.
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
– Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months, with reductions sustained through 12 months – – 86% of olezarsen-treated... Read more.
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership
First Contract Signed with MVM Group to Deliver VVER-440 Fuel to Paks Nuclear Power Plant WASHINGTON–(BUSINESS WIRE)–Westinghouse Electric Company and... Read more.
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
Sub-analysis of children with atopic dermatitis aged 2-17 in pivotal Phase 3 trials revealed early and clinically meaningful improvements in vIGA-AD™ and EASI-75... Read more.
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”
KYOTO, Japan–(BUSINESS WIRE)–OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering... Read more.